Answers are grounded in this paper and cite their sources.
Phase III trial compares PDL1V monotherapy with docetaxel in PD-L1-positive lung cancer, indicating potential benefits.
PDL1V (PF-08046054) is an investigational antibody-drug-conjugate that binds to programmed death ligand 1 (PD-L1)–expressing tumor cells and delivers cytotoxic agent monomethyl auristatin E (MMAE) through proteolytic cleavage of the mc-vc linker enabling preferential intracellular release of MMAE within target cells. PDL1V monotherapy has shown promising antitumor activity and manageable safety profile in patients with relapsed or refractory non-small cell lung cancer (NSCLC; Oliva et al., ESMO 2025; NCT05208762).
No takes yet. Share an insight, caveat, or question.
Girard et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: